Analysis of Tryptic Peptides from Therapeutic Monoclonal Antibodies Using LC-MS/MS
Immunotherapies are a hot topic, with the potential to impact our understanding of the immune system and treat a diverse array of conditions. Therapeutic monoclonal antibodies (mAbs) are part of this revolution, and clinical chemists are aware of the success of the biologic drugs. Antibodies are not just immunoassay reagents anymore but are also present in clinical serum samples from more and more patients each day. The clinical laboratory will have many roles as mAb therapies expand, including the development of new assays to differentiate a mAb from an endogenous, disease-causing clone and monitoring therapeutic drugs for better patient outcomes and assessing for the loss of response to therapy.
Therapeutic mAbs use has expanded significantly in the last 5 years, and depending on their target or their concentration, they may impact routine clinical testing for patients. Optimizing therapy during the induction phase to keep the mAb concentrations above certain thresholds has proven to be associated with improved responses and better outcomes in chronic conditions such as inflammatory bowel disease. This chapter will describe a LC-MS/MS protocol for analysis of tryptic peptides unique to infliximab (clonotypic peptides) for quantitation of the mAb. The protocol can be adapted to other mAbs with similar outcomes and is a useful, relatively simple strategy for measurement of mAbs.
Key wordsLC-MS/MS Infliximab Therapeutic monoclonal antibodies Trypsin Tryptic peptides Method development
The author would like to thank her colleagues Dr. Melissa R. Snyder and Dr. David L. Murray, who were mentors of this test development project, and Dr. David Barnidge and Paula Ladwig who were instrumental in the analytical development experiments and assay performance validation. The author reports an intellectual property/royalty income interest in an LC-MS/MS-based method for measurement of therapeutic monoclonal antibodies.
- 1.Ladwig PM, Barnidge DR, Willrich MAV (2017) Mass spectrometry approaches for identification and quantitation of therapeutic monoclonal antibodies in the clinical laboratory. Clin Vaccine Immunol 24(5). https://doi.org/10.1128/CVI.00545-16
- 5.Wang SL, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P, Lockton S, Ling N, Singh S (2012) Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods 382(1–2):177–188. https://doi.org/10.1016/j.jim.2012.06.002 CrossRefPubMedGoogle Scholar
- 8.Wang D, Wynne C, Gu F, Becker C, Zhao J, Mueller HM, Li H, Shameem M, Liu YH (2015) Characterization of drug-product-related impurities and variants of a therapeutic monoclonal antibody by higher energy C-trap dissociation mass spectrometry. Anal Chem 87(2):914–921. https://doi.org/10.1021/ac503158g CrossRefPubMedGoogle Scholar
- 9.Zhang B, Jeong J, Burgess B, Jazayri M, Tang Y, Taylor Zhang Y (2016) Development of a rapid RP-UHPLC-MS method for analysis of modifications in therapeutic monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 1032:172–181. https://doi.org/10.1016/j.jchromb.2016.05.017 CrossRefPubMedGoogle Scholar
- 10.Kohlhagen MC, Barnidge DR, Mills JR, Stoner J, Gurtner KM, Liptac AM, Lofgren DI, Vanderboom PM, Dispenzieri A, Katzmann JA, Willrich MA, Snyder MR, Murray DL (2016) Screening method for M-proteins in serum using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem. https://doi.org/10.1373/clinchem.2015.253781 CrossRefGoogle Scholar
- 11.Ladwig PM, Barnidge DR, Willrich MA (2016) Quantification of the IgG2/4 kappa monoclonal therapeutic Eculizumab from serum using Isotype specific affinity purification and microflow LC-ESI-Q-TOF mass spectrometry. J Am Soc Mass Spectrom. https://doi.org/10.1007/s13361-016-1566-y CrossRefGoogle Scholar
- 13.Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, Willrich MA, Barnidge DR, Dispenzieri A, Murray DL (2016) Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry. Clin Chem 62(10):1334–1344. https://doi.org/10.1373/clinchem.2015.253740 CrossRefPubMedGoogle Scholar
- 15.Ladwig PM, Barnidge DR, Snyder MR, Katzmann JA, Murray DL (2014) Quantification of serum IgG subclasses by use of subclass-specific tryptic peptides and liquid chromatography—tandem mass spectrometry. Clin Chem 60(8):1080–1088. https://doi.org/10.1373/clinchem.2014.222208 CrossRefPubMedGoogle Scholar
- 16.CLSI (2004) Evaluation of precision performance of quantitative measurement methods: approved guideline, 2nd edn. CLSI document EP05-A2 edn. Clinical and Laboratory Standards Institute, Wayne, PAGoogle Scholar